The companies have been involved in a joint research program since early 2017 to synthesize the compound uttroside-B and study its use for the treatment of liver cancer.
Uttroside-B, is a potent saponin, a type of chemical compound found in Black Nightshade shrub. Obtaining it can be challenging, but Chemvada developed a method to synthesize it.
Now, the plan is to ramp up production and go forward with pre-clinical testing and clinical trials.
READ: Q BioMed, Chemveda Life Sciences achieve potential chemotherapeutic breakthrough in liver cancer
As part of the deal, Q BioMed will pay Chemveda a mix of cash and stock as well as capped royalty on net sales. Chemveda will have first right of refusal and the right to manufacture any products that come out of the collaboration.
"Chemveda has been an excellent partner in this program, both in terms of execution and problem solving,” Q BioMed CEO Denis Corin said in a statement. “We look forward to the next phase as we advance this promising molecule and others towards the clinic.”
The companies have reason to be optimistic.
A 2016 Scientific Reports study found the compound to be 10 times more effective against the HepG2 liver cancer cell line than the then-only liver cancer drug approved by the US Food and Drug Administration.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel